Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2021-03-25 Remuneration Information
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA: Notice of Annual General Meeting on 15 April 2021
Remuneration Information Classification · 99% confidence The document is explicitly addressed 'To the shareholders of Ultimovacs ASA' and contains 'Recommendations by the Nomination Committee to the Annual General Meeting on April 15, 2021'. It details proposals regarding the election of Board Members and the remuneration for the Board and its committees, which are standard items presented for shareholder approval at an AGM. This content aligns perfectly with the materials presented during or in preparation for an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information). The document length is relatively short (2584 chars), but it is the substantive material itself (recommendations), not just an announcement that materials are available, making AGM-R more appropriate than RPA or RNS.
2021-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 15 April 2021
AGM Information Classification · 98% confidence The document explicitly states it is a 'Notice of Annual General Meeting' and provides the date, time, and location for the meeting. This directly corresponds to the definition of AGM Information (AGM-R). Although it mentions where documents are available, the primary purpose of this specific text is to call the meeting, making AGM-R the most accurate classification over RPA or RNS.
2021-03-25 English
Ultimovacs ASA: Annual Report 2020
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2020' and contains comprehensive sections including a Statement of the CEO, Directors' report, Corporate Governance Report, and Financial Statements for both the Group and the ASA. It covers the company's activities, clinical trial progress, and financial performance for the full fiscal year 2020. It is clearly the full annual report, not an announcement or a summary. FY 2020
2021-03-25 Norwegian
Ultimovacs ASA: Annual Report 2020
Report Publication Announcement Classification · 100% confidence The document explicitly states 'Ultimovacs ASA: Annual Report 2020' in the title and body. However, the text is very short (959 characters) and functions as an announcement stating that the Board of Directors 'has approved the Annual Report for 2020' and that a PDF version is 'enclosed' and available on the website. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report is attached or published should be classified as a Report Publication Announcement (RPA), not the report itself (10-K).
2021-03-25 English
Ultimovacs ASA: New share capital registered
Share Issue/Capital Change Classification · 99% confidence The document explicitly states 'New share capital registered' and details the resulting change in the total number of shares and the new share capital amount (NOK 3,200,326.10 divided into 32,003,261 shares). This directly relates to a change in the company's capital structure due to a share issuance (mentioned as part of an employee incentive program). This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA). The document is short and is a direct announcement of the registration of the capital change, not an announcement of a report.
2021-03-11 English
Ultimovacs ASA: Share capital increase related to exercise of options
Share Issue/Capital Change Classification · 99% confidence The document explicitly states that the Board of Directors resolved to increase the Company's share capital by issuing new shares (29,750 new shares) related to an employee incentive program. This action directly relates to changes in the company's capital structure through the issuance of new stock. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not a general regulatory filing (RNS) because it is highly specific to a capital event, nor is it a transaction in own shares (POS) as it is an issuance related to options/incentives, which is better captured by SHA.
2021-03-08 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.